Cabazitaxel was FDA approved this season for that treatment of hormone refractory prostate cancer. In a Phase III study, patients with hormone and docetaxel Vortioxetine (Lu AA21004) hydrobromide refractory metastatic prostate cancer were addressed with cabazitaxel or mitoxantrone, patients in the experimental arm had statistically enhanced median OS compared to those in the mitoxantrone arm and median PFS was doubled within the cabazitaxel party. However, the most men experienced grade 3 neutropenia, and a portion experienced febrile neutropenia, and all degrees PN, thus careful patient selection and growth factor support to stop prolonged neutropenia might be justified, especially in high risk populations including the elderly. In conclusion, paclitaxel and docetaxel continue being utilized widely in the administration of different malignan?cies despite their drawbacks, for example, bad drug solubility, toxicities and emergence Posttranslational modification of drug resistance. Constant drug development efforts are in place trying to find new less-toxic and more active analogs with new preparations to over come these dilemmas, but to date nearly all of these novel compounds didn’t show the clinical superiority within the parent com?pounds. Presently, Abraxane and cabazitaxel will be the recent FDA-APPROVED taxane additions to our scientific anti-neoplastic drug armamentarium. Furthermore, the recent successful clini?cal introduction of novel nontaxane microtubule targeting chemotherapy agents including eribulin and epothilones is likely to help restrict the development of novel taxanes and formulations. As recently as the start of the 21st century, metastatic castration resistant prostate cancer had a bleak prognosis. The available remedies, such as for example radiotherapy, boneseeking isotopes, bisphosphonates, chemotherapy, corticosteroids and analgesics, presented palliation of symptoms, but no improvement in survival. 1 In the past 8 years, the outlook has changed dramatically. First, the landmark TAX327 Cediranib molecular weight demo of docetaxel demonstrated that, despite previous knowledge, 2 mCRPC was tuned in to chemotherapy with regards to patient survival. . 1 Then, in 2010, after 6 years with no treatment offering a survival benefit in the post docetaxel environment, phase III data on cabazitaxel showed that people could derive further survival benefit from second-line chemotherapy. 3 In 2011, the hormonal agent abiraterone was also reported to improve survival in patients previously treated with docetaxel. 4 Both cabazitaxel and abiraterone are now authorized for use in Canada for the treating mCRPC that’s progressed throughout or after docetaxel based chemotherapy. In addition, evidence is accumulating from trials of other agents, perhaps not yet permitted in Canada, that provide a survival benefit in mCRPC.